Nuvation Bio Inc. Other Comprehensive Income (Loss), Net of Tax
Nuvation Bio Inc. (NUVB) reported Other Comprehensive Income (Loss), Net of Tax of -$463.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- Nuvation Bio Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$463.00K.
- Nuvation Bio Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$1.22M.
- Nuvation Bio Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $501.00K, a 85.22% decline year-over-year.
- Nuvation Bio Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$225.00K.
- Nuvation Bio Inc. other comprehensive income (loss), net of tax for fiscal 2025 was $741.00K.
- Nuvation Bio Inc. other comprehensive income (loss), net of tax for fiscal 2024 was -$145.00K, a 102.54% decline from fiscal 2023.
- Nuvation Bio Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $5.71M.
- Nuvation Bio Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$4.34M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$463.00K 10-Q · filed 2026-08-06 | -$1.69M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$1.22M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $741.00K 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $501.00K 10-Q · filed 2025-11-03 | $276.00K derived: sum of 2 quarters · filed 2026-08-06 | -$217.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$225.00K 10-Q · filed 2026-08-06 | -$718.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$493.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | -$145.00K 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $3.39M 10-Q · filed 2025-11-03 | $3.14M derived: sum of 2 quarters · filed 2025-11-03 | $1.79M derived: sum of 3 quarters · filed 2025-11-03 | |
| 2024-06-30 | -$245.00K 10-Q · filed 2025-11-03 | -$1.59M derived: sum of 2 quarters · filed 2025-11-03 | ||
| 2024-03-31 | -$1.35M 10-Q · filed 2025-11-03 | |||
| 2023-12-31 | $5.71M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $1.10M 10-Q · filed 2024-11-06 | -$360.00K derived: sum of 2 quarters · filed 2024-11-06 | $2.23M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$1.46M 10-Q · filed 2024-11-06 | $1.13M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $2.59M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | -$4.34M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | -$1.14M 10-Q · filed 2023-11-02 | -$1.90M derived: sum of 2 quarters · filed 2023-11-02 | -$6.93M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$761.00K 10-Q · filed 2023-11-02 | -$5.79M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | -$5.03M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | -$2.74M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | -$369.00K 10-Q · filed 2022-11-03 | -$593.00K derived: sum of 2 quarters · filed 2022-11-03 | -$1.17M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$224.00K 10-Q · filed 2022-11-03 | -$800.00K derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | -$576.00K 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $1.14M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | -$350.00K 10-Q · filed 2021-11-10 | $581.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.40M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $931.00K 10-Q · filed 2021-11-10 | $1.75M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $819.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |